Biotech Strategy Blog

Commentary on Science, Innovation & New Products

About Pieter Droppert

Here are my most recent posts

Posts by Pieter Droppert

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

The Food and Drug Administration (FDA) today approved Roche/Genentech’s obinutuzumab (Gazyva), also known as GA101, for untreated Chronic Lymphocytic Leukemia (CLL) in combination with the chemotherapy chlorambucil. Updated CLL11 trial data will be presented at the 2013 annual meeting of the American Society of Hematology (twitter #ASH13) in New Orleans from December 7-10. Gazyva is the first drug with a Breakthrough Therapy Designation to be approved by the FDA.

Leave a comment